Stock AnalizRoivant Sciences (ROIV) earnings for the quarter ended September 2026: EPS beats estimates
Roivant Sciences reported results for the quarter ended September 2026 on November 9, 2026. Adjusted earnings per share came in at -$0.18 against the analysts’ average forecast of -$0.45, a beat of 58.9%.
Revenue for the quarter was $35 million, up 2135.6% from $2 million in the same quarter a year earlier.
The market’s verdict: the stock rose 4.6% on the first trading day after the report.
The last four quarters
Roivant Sciences has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$0.18 | -$0.45 | +58.9% | +2136% | +4.6% |
| Jun 2026 | -$0.34 | -$0.36 | +4.9% | −34% | +5.0% |
| Mar 2026 | -$0.32 | -$0.35 | +9.3% | −67% | +9.5% |
| Dec 2025 | -$0.38 | -$0.31 | −22.0% | −78% | +30.9% |
What comes next
Analysts expect EPS of -$0.45 for the next quarter on average and -$1.47 for the fiscal year ending March 31, 2027.
The average analyst price target is $50.82, 29% above the current price of $39.53.
Valuation and score
Roivant Sciences scores 0.8 out of 5 overall on Stock Analiz (weak). Full Roivant Sciences analysis with 10 years of financials
Frequently asked questions
What was Roivant Sciences’s EPS for the quarter ended September 2026?
-$0.18 adjusted per share, against an analyst consensus of -$0.45.
How much revenue did Roivant Sciences report?
$35 million, up 2135.6% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.